Current disease modifying antirheumatic drug (DMARD) treatment in outpatients with RA in rheumatological care with respect to rheumatoid factor (1998; values are percentages)
| Seropositive RA (n=5948) | Seronegative RA (n=2999) | Total (n=8947) | |
| Single treatments | |||
| Antimalarial drugs | 6.63-150 | 15.6 | 8.9 |
| SSZ3-151 | 7.63-150 | 11.7 | 9.0 |
| Parenteral gold | 5.1 | 6.1 | 5.4 |
| MTX3-151 | 45.73-150 | 36.6 | 42.7 |
| AZA3-151 | 3.3 | 2.5 | 3.1 |
| Other DMARDs | 4.7 | 4.4 | 4.6 |
| Combination treatments | |||
| MTX with antimalarial drugs | 5.63-150 | 3.0 | 4.7 |
| MTX with SSZ | 3.63-150 | 1.9 | 3.0 |
| Other combination with MTX | 5.83-150 | 3.2 | 4.9 |
| Other combination without MTX | 2.2 | 1.4 | 1.9 |
| Total of combinations | 17.13-150 | 9.5 | 14.6 |
| Total | |||
| Antimalarial drugs | 14.33-150 | 17.7 | 15.5 |
| SSZ | 12.7 | 14.5 | 13.3 |
| MTX | 60.83-150 | 44.9 | 55.5 |
| Any DMARD | 90.33-150 | 84.4 | 88.3 |